Search

Author/Creator Karam, Jose Antonio

1. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Issue 10358 (1st October 2022)

Authors:
Pal, Sumanta Kumar; Uzzo, Robert; Karam, Jose Antonio; Master, Viraj A; Donskov, Frede; Suarez, Cristina; Albiges, Laurence; Rini, Brian; Tomita, Yoshihiko; Kann, Ariel Galapo; Procopio, Giuseppe; Massari, Francesco; Zibelman, Matthew; Antonyan, Igor; Huseni, Mahrukh; Basu, Debasmita; Ci, Bo; Leu...
Journal:
Lancet
Issue:
Volume 400:Issue 10358(2022)
Page Start:
1103
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2022)

Authors:
Powles, Thomas; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Ferguson, Thomas; Symeonides, Stefan N; Hajek, Jaroslav; Gurney, Howard; Chang, Yen-Hwa; Lee, Jae Lyun; Sarwar, Naveed; Thiery-Vuillemin, Antoine; Gross-Goupil, Marine; Mahave, Mauricio; Haas, Naomi B; Sawrycki, Piotr; Burgents, Jo...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 9(2022)
Page Start:
1133
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search